Natco has received approval from the Drug Controller General of India (DCGI) for Baricitinib earlier in May. Natco went ahead and launched the drug under brand name Barinat even as its compulsory licensing application is still pending before India. The patents of Baricitinib are owned by Lilly.COVID-19 drug Baricitinib: Eli Lilly signs voluntary licensing agreement with Natco Pharma
Natco has received approval from the Drug Controller General of India (DCGI) for Baricitinib earlier in May. Natco went ahead and launched the drug under brand name Barinat even as its compulsory licensing application is still pending before India. The patents of Baricitinib are owned by Lilly.
Subscribe to:
Post Comments (Atom)
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment